FDA WARNING_LETTER - SSS AUSTAR LLC - March 01, 2026

On March 5, 2026, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products issued a Warning Letter to SSS AUSTAR LLC, an entity selling and distributing nicotine pouch products in the United States. The letter, referenced ER2601424, was a result of the FDA"s review of inspection records, which determined that the company markets "new tobacco products" without the necessary premarket authorization. The primary violation concerns the product "ZIMO MINT 6MG," identified as a new tobacco product because it was not commercially marketed in the U.S. as of February 15, 2007, and lacks an FDA marketing authorization order. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), products like these containing nicotine from any source are considered tobacco products subject to FDA jurisdiction. Without the required authorization, the product is deemed both "adulterated" and "misbranded" under specific sections of the FD&C Act. SSS AUSTAR LLC is required to take prompt action to address these violations. Specifically, the company must immediately discontinue the sale and distribution of all unauthorized tobacco products. Furthermore, a written response detailing actions taken to resolve the violations, including the dates of discontinuation and a plan for maintaining future compliance, must be submitted to the FDA within 15 working days of receiving the letter. Failure to comply may lead to further regulatory action, such as civil money penalties or product seizure.